Pro Medicus Limited (PMCUF) Stock: Price, Forecast & Analyst Target
Pro Medicus Limited (PMCUF) — price $118.64 (-8.03%), as of the Oct 26, 2026 trading session; market cap $12.4B.
Educational signal · not a buy or sell recommendation · How to read this
Pro Medicus Limited · PMCUF
Pro Medicus Limited (PMCUF) specializes in healthcare imaging software and services, catering to hospitals and diagnostic imaging groups across multiple regions. With a strong market presence and innovative product offerings, the company is well-positioned in the healthcare information services sector.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $118.64 | |
| Change on the day | -8.03% | |
| 52-week range | $74.52 – $192.57 | |
| Market capitalisation | $12.4B | |
| Price / earnings (trailing) | 79.22 | |
| Shares traded on the day | 13 |
Price & events
Other perspectives
Council score for Pro Medicus (PMCUF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 25, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the PMCUF film — every key number, told as a short cinematic story
~2 min · open the film
What is Pro Medicus (PMCUF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pro Medicus Limited (PMCUF) is the company analyzed here. It employs 153 people and is led by Sam Aaron Hupert. In Q4 FY2026 it reported revenue of $96M and net income of $66M. The market values it at $12.4B.
What do the latest results show for Pro Medicus (PMCUF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $96M. Against analyst estimates the company has EPS beat 6 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $96M | $66M | $0.62 (diluted) |
| Q2 FY2026 | $88M | $120M | $1.14 (diluted) |
| Q4 FY2025 | $81M | $45M | $0.43 (diluted) |
| Q2 FY2025 | $68M | $36M | $0.34 (diluted) |
What are the financial strengths and risks for Pro Medicus (PMCUF)?
Short answer
The distress and quality screens read Altman Z 75.34 · Piotroski F 6. Trailing ratios: ROE 63.2% · ROA 43.5% · current ratio 6.82 · earnings yield 1.6% · free-cash-flow yield 0.7%.
What should you watch next at Pro Medicus (PMCUF)?
Short answer · as of
Current published price targets run low $155.00 · high $155.00 · consensus $155.00 · median $155.00 against a quoted price of $118.64 (as of Oct 26, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $155.00 – $155.00
- Consensus target
- $155.00
- Median target
- $155.00
Consensus record · Captured .
Measured against a quoted price of $118.64 (as of Oct 26, 2026).
What Investors Ask About Pro Medicus (PMCUF)
These answers are editorial: 1 of these 8 answers is drawn from the PMCUF research dossier (written Mar 17, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PMCUF a good stock to buy?
Stock Expert AI does not rate PMCUF buy, sell or hold. Pro Medicus Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PMCUF stock price today?
The last price recorded on this page for Pro Medicus Limited (PMCUF) is $118.64, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PMCUF price target?
The analyst consensus price target for Pro Medicus Limited (PMCUF) is $155.00 (range $155.00 to $155.00, median $155.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for PMCUF?
Pro Medicus Limited faces several risks, including regulatory changes that could impact its product offerings and market access. Additionally, intense competition in the healthcare technology sector may pressure pricing and market share. Economic downturns could also lead to reduced healthcare spending, affecting revenue growth.
What are the key factors to evaluate for PMCUF?
Evaluate PMCUF on fundamentals, analyst consensus, and risk factors. P/E: 79.22x. Analysts target $155.00 (+31%). Not financial advice.
How frequently does PMCUF data refresh on this page?
PMCUF's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PMCUF's recent stock price performance?
Pro Medicus Limited (PMCUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margins indicating strong operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMCUF overvalued or undervalued right now?
Pro Medicus Limited (PMCUF) trades at 79.22x earnings. Analysts target $155.00 (+31%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 13 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $118.64 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T17:04:38.095Z. | |
px.change | Change on the day | -8.03% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.4B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:00.000Z. Captured from FMP at 2026-10-26T17:04:36.943Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$10.36 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 79.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 13 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2026 | $96M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2026 | $66M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $155.00 · high $155.00 · consensus $155.00 · median $155.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $155.00 – $155.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $155.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $155.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $74.52 – $192.57 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.employees | Employees | 153 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.ceo | Chief executive | Sam Aaron Hupert | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-19 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 75.34 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 63.2% · ROA 43.5% · current ratio 6.82 · earnings yield 1.6% · free-cash-flow yield 0.7% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.